ACY-738 (ACY738) is a novel, potent, selective, brain penetrable and orally-bioavailable HDAC6 inhibitor with neuroprotective and anticancer activities.

LMK-235 (LMK235) is a novel, potent and selective inhibitor of HDAC4 and HDAC5 (histone deacetylase) with potential antitumor activity.

NCT-14b (TCS-HDAC6; NCT14b; TCS HDAC6) is a novel, potent and selective inhibitor of histone deacetylase 6 (HDAC6) with anticancer activity.

Sodium phenylbutyrate (4-Phenylbutyric acid sodium; 4-PBA sodium), an orphan drug marketed by Ucyclyd Pharma, is a novel and potent histone deacetylase (HDAC) inhibitor used as an as adjunctive therapy for chronic treatment of urea cycle disorders involving deficiencies of argininosuccinic acid synthetase (AS), ornithine transcarbamylase (OTC), or carbamylphosphate synthetase (CPS). .

Domatinostat (formerly known as 4SC-202) is a novel class I HDAC inhibitor (HDACi) that potently inhibited survival and proliferation of primary human colon cancer cells and established CRC lines (HT-29, HCT-116, HT-15, and DLD-1). It has IC50 values of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively.

SIS17 is a novel, potent and isoform-selective inhibitor of mammalian histone deacetylase 11 (HDAC 11) with an IC50 value of 0.83 μM.

BG45 (BG-45) is a novel, potent and selective class I HDAC inhibitor with potential anticancer activity.

Entinostat (formerly known as MS-275; SNDX-275) is a potent, benzamide-based and class-selective but generally pan-HDAC (histone deacetylase) inhibitor with potential anticancer activity.

Droxinostat (formerly NS-41080) is a novel, potent, selective inhibitor of histone deacetylase (HDAC) with potential anticancer activity.

RG-2833 (formerly RGFP-109) is a potent, selective and brain-permeable inhibitor of HDAC (histone deacetylase) with potential neuroprotective effects.